Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Abruzzo, Lynne V., Andersen, Barbara L., Awan, Farrukh T., Bhat, Seema A., Dean, Allison, Lucas, Margaret, Banks, Christin, Grantier, Cara, Heerema, Nyla A., Lozanski, Gerard, Maddocks, Kami J., Valentine, Thomas R., Weiss, David M., Jones, Jeffrey A., Woyach, Jennifer A., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7605394/
https://ncbi.nlm.nih.gov/pubmed/32795224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00491
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados